Report ID: SQMIG15E2442
Report ID:
SQMIG15E2442 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
63 |
Figures:
75
The worldwide mitomycin market has a low level of competition. A few players wield considerable power, including Kyowa-kirin, Intas Pharmaceuticals, Speciality European Pharma, Teva Pharmaceuticals, Bristol-Myers Squibb, Rocket Pharmaceuticals, and Aspen. These firms are continually attempting to produce improved items in order to provide their customers with highly efficient medications. As an example: Rocket Pharma has announced the start of a stage 2 study for a medication intended to be used in gene therapy for the treatment of fanconi anaemia, a rare condition. This trial stage will largely assess this drug's resistance to mitomycin C, a DNA damaging chemo agent, over a one-year period.
Mitomycin Market Top Player's Company Profiles
Mitomycin Market
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONMitomycin Market size was valued at USD 161.1 million in 2019 and is poised to grow from USD 175.7 million in 2023 to USD 362.2 million by 2031, growing at a CAGR of 9.1% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG15E2442